Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Payables (2016 - 2025)

Historic Payables for Ascendis Pharma A (ASND) over the last 10 years, with Q3 2025 value amounting to $863.5 million.

  • Ascendis Pharma A's Payables rose 1811.16% to $863.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $863.5 million, marking a year-over-year increase of 1811.16%. This contributed to the annual value of $763.3 million for FY2024, which is 4142.32% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Payables stood at $863.5 million, which was up 1811.16% from $790.5 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Payables ranged from a high of $863.5 million in Q3 2025 and a low of $53.2 million during Q2 2021
  • Its 5-year average for Payables is $368.3 million, with a median of $133.0 million in 2023.
  • Per our database at Business Quant, Ascendis Pharma A's Payables skyrocketed by 45940.09% in 2024 and then tumbled by 429.32% in 2025.
  • Ascendis Pharma A's Payables (Quarter) stood at $76.0 million in 2021, then surged by 51.29% to $114.9 million in 2022, then surged by 369.59% to $539.8 million in 2023, then skyrocketed by 39.63% to $753.6 million in 2024, then grew by 14.57% to $863.5 million in 2025.
  • Its Payables was $863.5 million in Q3 2025, compared to $790.5 million in Q2 2025 and $745.3 million in Q1 2025.